Depression With Psychosis: Symptoms and Care

Main topic: Addiction and mental health

At a Glance: Depression With Psychosis

• What is depression with psychosis?
  • A severe form of depression, also called major depressive disorder with psychotic features, that includes hallucinations or delusions.
• How common is it?
  • Around 1 in 5 people with major depressive disorder experience psychotic features during an episode.
• What causes it?
  • Contributing factors include genetics, brain chemistry, stressful life events, medical conditions, and substance use.
• What are the main symptoms?
  • Intense sadness, hopelessness, guilt, plus delusions or hallucinations that reflect the depressed mood.
• How is it treated?
  • Typically with a combination of an antidepressant and an antipsychotic. Electroconvulsive therapy (ECT) may be used in severe cases.
• Is hospitalization necessary?
  • Sometimes, especially when suicide risk is high or safety is a concern.
• How does substance use affect it?
  • Alcohol and drugs can worsen depression and psychosis. Integrated treatment for both conditions is most effective.

What this article covers

• What depression with psychosis is and how it differs from other conditions
• Signs and symptoms to watch for
• Causes, risk factors, and the link with substance use
• How clinicians diagnose it
• Evidence‑based treatments and when hospital care is needed
• Practical steps for loved ones and where to find help

‹›

Understanding depression with psychosis

Definition and key features

Depression with psychosis, also called major depressive disorder with psychotic features, is a period of major depression that includes a loss of contact with reality. People experience the usual depressive symptoms along with hallucinations (seeing or hearing things not there) and/or delusions (fixed false beliefs). The content of these symptoms often mirrors the person’s low mood, such as beliefs of guilt, illness, or failure.

How common is it?

Epidemiologic research estimates a current‑episode prevalence of 0.4% in the general population, and that about 18% of major depressive episodes include psychotic features. Rates are generally higher in women, and they may rise with age.

Signs and symptoms

Freedom Starts Here. Take Back Your Life Today.

Same-Day Admissions in Austin Available.

Call (512) 605-2955 Verify insurance

Causes and risk factors

Substance use and addiction

Alcohol and drugs (including cannabis, stimulants, and hallucinogens) can trigger or intensify psychosis in vulnerable people. If stimulants are part of the picture, our guide to amphetamine psychosis (stimulant psychosis) explains warning signs, timelines, and treatment steps.

Depression itself can also lead to increased use of alcohol or drugs as a coping strategy, which can worsen mood and safety. This is why integrated treatment for co‑occurring substance use disorder (SUD) and depression is important.

Substance use can trigger or worsen psychotic symptoms; learn how residential care supports recovery from drug‑induced psychosis and lowers relapse risk.

Diagnosis

Treatment

Prognosis and recovery

Depression with psychosis and addiction

Why they co‑occur

Depression can lead some people to use alcohol or drugs to cope. Substance use can worsen mood, interact with medicines, and raise the risk of psychosis in vulnerable individuals. The combination raises safety concerns and complicates care.

What effective, integrated care looks like

• One team addresses both the mood disorder and the SUD
• Medication plans consider interactions and withdrawal risks
• Therapy focuses on mood, cravings, and relapse prevention
• Family education and peer support reinforce goals
• Talk with your care team about programs that treat co‑occurring disorders in the same setting.

For integrated care that addresses substance use and dual diagnosis treatment alongside depression with psychosis, see our Austin program.

When to seek urgent help

How Nova Recovery Center Supports Substance Abuse Treatment with Co-Occurring Depression with Psychosis

At Nova Recovery Center, we understand that many individuals face the complex challenge of substance abuse as a primary diagnosis while also living with depression with psychosis as a secondary condition. Our treatment model is designed to address both issues simultaneously, ensuring that no part of a person’s health is overlooked. Through a structured, evidence-based approach, we provide comprehensive addiction treatment that includes medical care, therapy, and relapse prevention strategies.

At the same time, our clinical team carefully monitors and supports clients with co-occurring depression with psychosis, tailoring care to meet their specific needs. By integrating psychiatric support with addiction treatment, we reduce the risk of relapse and improve overall mental health outcomes. Clients benefit from a safe, supportive environment where they can work through the challenges of both substance use and mental health conditions. We emphasize long-term recovery by offering tools that help clients manage triggers, build coping strategies, and develop healthier thought patterns.

With a continuum of care that extends from detox through aftercare, Nova Recovery Center is committed to guiding individuals toward stability, hope, and sustainable recovery.

Other Drug and Alcohol Rehab Locations

• 

  Austin

  Drug Detox in Austin, Texas →

• 

  San Antonio

  Drug Detox in San Antonio, Texas →

• 

  Houston

  Drug Detox in Houston, Texas →

Medical Disclaimer

The information on this page is provided for educational purposes only and should not be taken as a substitute for professional medical advice, diagnosis, or treatment. Prescription medications, including antidepressants and antipsychotics, should only be used under the supervision of a qualified healthcare provider. Never start, stop, or adjust any medication without first consulting your doctor. If you are experiencing severe side effects, worsening symptoms, or thoughts of self-harm, call 911 in the United States or seek immediate medical assistance. For confidential mental health support, you can dial 988 to connect with the Suicide & Crisis Lifeline, available 24 hours a day.

Nova Recovery Center Editorial Guidelines

By instituting a policy, we create a standardized approach to how we create, verify, and distribute all content and resources we produce. An editorial policy helps us ensure that any material our writing and clinical team create, both online and in print, meets or exceeds our standards of integrity and accuracy. Our goal is to demonstrate our commitment to education and patient support by creating valuable resources within our realm of expertise, verifying them for accuracy, and providing relevant, respectful, and insightful data to our clients and families.

References

1. National Health Service (NHS). (2023, April 13). Psychotic depression. NHS: Psychotic depression
2. MedlinePlus. (2024, October 20). Major depression with psychotic features. U.S. National Library of Medicine. MedlinePlus: Ency
3. National Institute of Mental Health. (n.d.). Depression. (Brochure). Retrieved September 30, 2025, from NIMH: Depression
4. National Institute of Mental Health. (n.d.). Understanding psychosis. (Fact sheet). Retrieved September 30, 2025, from NIMH: Understanding psychosis
5. National Institute for Health and Care Excellence (NICE). (2022). Depression in adults: Treatment and management (NG222). nice.org.uk: Guidance
6. Meyers, B. S., Flint, A. J., Rothschild, A. J., Mulsant, B. H., Whyte, E. M., Peasley‑Miklus, C., Heo, M., & the STOP‑PD Group. (2009). A double‑blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: The Study of Pharmacotherapy of Psychotic Depression (STOP‑PD). Archives of General Psychiatry, 66(8), 838–847. https://doi.org/10.1001/archgenpsychiatry.2009.79
7. Flint, A. J., Meyers, B. S., Rothschild, A. J., Whyte, E. M., Alexopoulos, G. S., Rudorfer, M., Marino, P., Banerjee, S., Pollari, C. D., Wu, Y., Voineskos, A. N., & Mulsant, B. H. (2019). Effect of continuing olanzapine vs placebo on relapse among patients with psychotic depression in remission: The STOP‑PD II randomized clinical trial. JAMA, 322(7), 622–631. https://doi.org/10.1001/jama.2019.10517
8. Kruizinga, J., Liemburg, E., Burger, H., Cipriani, A., Geddes, J., & Nolen, W. A. (2021). Pharmacological treatment for psychotic depression. Cochrane Database of Systematic Reviews, 2021(12), CD004044. https://doi.org/10.1002/14651858.CD004044.pub5
9. Ohayon, M. M., & Schatzberg, A. F. (2002). Prevalence of depressive episodes with psychotic features in the general population. American Journal of Psychiatry, 159(11), 1855–1861. https://doi.org/10.1176/appi.ajp.159.11.1855
10. Petrides, G., Fink, M., Husain, M. M., Knapp, R. G., Rush, A. J., Mueller, M., Rummans, T. A., O’Connor, K., Rasmussen, K. G., Bernstein, H. J., Biggs, M., Bailine, S. H., Kellner, C. H., & CORE. (2001). ECT remission rates in psychotic versus nonpsychotic depressed patients: A report from CORE. Journal of ECT, 17(4), 244–253. https://pubmed.ncbi.nlm.nih.gov/11731725/
11. National Institute on Drug Abuse. (n.d.). Co‑occurring disorders and health conditions. Retrieved September 30, 2025, from https://nida.nih.gov/research-topics/co-occurring-disorders-health-conditions
12. 988 Suicide & Crisis Lifeline. (n.d.). Media resources. Retrieved September 30, 2025, from https://988lifeline.org/current-news/media-resources/